Localized palmar vancomycin-induced linear IgA bullous dermatosis occurring at supratherapeutic levels.
Walsh
Sarah N
SN
Kerchner
Katherine
K
Sangüeza
Omar P
OP
D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000888:Antibodies, Anti-Idiotypic / Q000032:analysis; D016470:Bacteremia / Q000188:drug therapy; D001706:Biopsy; D003176:Complement C3 / Q000378:metabolism; D003937:Diagnosis, Differential; D004817:Epidermis / Q000378:metabolism / Q000473:pathology; D019085:Fluorescent Antibody Technique, Direct; D005500:Follow-Up Studies; D006229:Hand Dermatoses / Q000139:chemically induced* / Q000276:immunology / Q000473:pathology; D006801:Humans; D007070:Immunoglobulin A / Q000276:immunology / Q000378:metabolism; D008297:Male; D012872:Skin Diseases, Vesiculobullous / Q000139:chemically induced* / Q000276:immunology / Q000473:pathology; D013203:Staphylococcal Infections / Q000188:drug therapy; D014640:Vancomycin / Q000008:administration & dosage / Q000009:adverse effects*
D000900:Anti-Bacterial Agents; D000888:Antibodies, Anti-Idiotypic; D003176:Complement C3; D007070:Immunoglobulin A; D014640:Vancomycin